AG-URSODIOL TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

şimdi satın al

Ürün özellikleri Ürün özellikleri (SPC)
26-09-2023

Aktif bileşen:

URSODIOL

Mevcut itibaren:

ANGITA PHARMA INC.

ATC kodu:

A05AA02

INN (International Adı):

URSODEOXYCHOLIC ACID

Doz:

500MG

Farmasötik formu:

TABLET

Kompozisyon:

URSODIOL 500MG

Uygulama yolu:

ORAL

Paketteki üniteler:

15G/50G

Reçete türü:

Prescription

Terapötik alanı:

CHOLELITHOLYTIC AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0122789002; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2020-09-23

Ürün özellikleri

                                AG-Ursodiol (Ursodiol Tablets)
_ _
Page 1 of 32
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AG-URSODIOL
Ursodiol Tablets
Tablets, 250 mg & 500 mg, Oral
USP
Bile Acid Preparation
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
September 23, 2020
Date of Revision:
September 26, 2023
Submission Control Number: 278847
AG-Ursodiol (Ursodiol Tablets)
_ _
Page 2 of 32
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Gastrointestinal
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED .
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
............................................................................................................
4
1.1
Pediatrics
.............................................................................................................................
4
1.2
Geriatrics
.............................................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
...............................................................................
4
4.1
Dosing Considerations
........................................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
................................................................... 5
4.3
Administration
....................................................................................................................
5
4.4
Missed Dose
.....................
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Ürün özellikleri Ürün özellikleri Fransızca 26-09-2023

Belge geçmişini görüntüleyin